Insulet Corporation
Performance
株価チャート
業績・財務
業績・財務
| 売上高 | $761.70M |
| 営業利益 | $122.20M |
| 税引前利益 | $113.00M |
| 純利益 | $91.10M |
| 営業利益率 | 16.0% |
| ROE | 7.0% |
| ROA | 3.0% |
| 自己資本比率 | 43.6% |
| 総資産 | $2.99B |
| 純資産 | $1.30B |
業績推移
売上・利益の推移
ROE・ROA の推移
詳細指標
詳細指標
| ROIC | — |
| ROE | 23.00% |
| ROA | 9.74% |
| FCFマージン | 8.73% |
| 粗利益率 | 71.01% |
| 営業利益率 | 16.03% |
| 営業CFマージン | 21.35% |
| 配当性向 | 0.00% |
| 配当成長率(3年) | — |
| Net Debt/EBITDA | 77.84 |
| 実効税率 | — |
| 自社株買い傾向 | — |
バランスシート
バランスシート
| ネットキャッシュ | -$1.20B |
| NC比率 | -11.4% |
| 流動資産 | $1.71B |
| 有価証券 | — |
| 現金 | $480.40M |
| 負債総額 | $1.68B |
| 時価総額(BS時点) | $10.55B |
企業情報
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
| ウェブサイト | https://www.insulet.com |
| CEO | Ms. Ashley A. McEvoy |
| 従業員数 | 5,400人 |
| 住所 | 100 Nagog Park, Acton, 01720, United States |
| 電話番号 | 978 600 7000 |
| 取引所 | NMS |
| 国 | United States |